BACARDI-LIMITED
16.9.2022 16:05:40 CEST | Business Wire | Press release
Bacardi Limited, the largest privately held spirits company in the world, today announces moves within its global marketing leadership. John Burke, Global Chief Marketing Officer of Bacardi and President of Bacardi Global Brands Limited, will retire after more than 28 years with the company at the end of 2022. During his tenure, he led many of the company’s leading brands, including most recently BACARDÍ® rum, BOMBAY SAPPHIRE® gin, MARTINI® vermouths and sparkling wines, and DEWAR’S® Blended Scotch whisky.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220916005301/en/
Ned Duggan will be promoted to Global Chief Marketing Officer of Bacardi and President of Bacardi Global Brands Limited. (Photo: Business Wire)
“John is an incredibly strategic marketer who has helped us reinvigorate many brands and keep consumer at the heart of everything that we do. He played an important role in creating a disciplined marketing organization focused on building capabilities and driving brand equity over the years,” says Mahesh Madhavan, Chief Executive Officer of Bacardi Limited. “Under his leadership, we have seen many magical moments for our brands. He leaves us having imprinted his mark in our story – and a legacy he can be very proud of.”
“I am incredibly grateful for the many opportunities I have been given in my lifetime at Bacardi. I have had the opportunity to work with and learn from some remarkable people, and I hope I have been able to help them in return. I have loved nurturing our brands to make them stronger and see them grow,” says John Burke. “I am very proud of what we have achieved together and wish Bacardi good fortune and continued success for the future.”
Following John’s retirement, Ned Duggan will be promoted to Global Chief Marketing Officer of Bacardi and President of Bacardi Global Brands Limited. Since 2017, Ned has led BACARDÍ® rum, first in market execution in North America and later globally from Bermuda as SVP. In addition to his continued leadership of BACARDÍ rum, he will add MARTINI®, DEWAR’S®, WILLIAM LAWSON’S®, D’USSÉ® Cognac, among others. Ned’s ascension is the culmination of a 17-year-tenure at Bacardi that began as an Assistant Brand Manager. His career has spanned assignments at regional and global levels working on many company brands, including DEWAR’S®, GREY GOOSE®, BOMBAY SAPPHIRE®, OXLEY®, ST-GERMAIN®, D’USSÉ®, and others. Ned, who will relocate to London, will report to CEO Mahesh Madhavan and joins the Global Leadership Team (GLT).
“I am incredibly honored and humbled to assume the role of CMO at Bacardi,” says Ned Duggan. “I have spent my career at this company, learning from the best and I am thrilled to enter this next phase of my journey working to further develop and grow our renowned portfolio.”
Kathy Parker, President & CMO of GREY GOOSE® vodka and the tequila portfolio, which includes PATRÓN® and CAZADORES®, will add BOMBAY SAPPHIRE® gin to her remit following John’s retirement. Kathy is a member of the company’s Global Leadership Team and reports to CEO Mahesh Madhavan.
About Bacardi Limited
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 160 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000, operates production facilities in 10 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on Twitter, LinkedIn or Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220916005301/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release
New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
Boomi Teams up With Gong to Bring Revenue AI to Boomi Agentstudio14.5.2026 18:00:00 CEST | Press release
Gong's revenue AI is now natively available in the Boomi Enterprise Platform Boomi, the data activation company for AI, today announced a collaboration withGong, the leader in Revenue AI, to bring revenue signals captured in Gong natively into the Boomi Enterprise Platform. This collaboration enables enterprises to establish an active data foundation designed to transform customer conversations into coordinated, automated actions across systems and functions enterprise-wide with Boomi Agentstudio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514443012/en/ Boomi Teams Up with Gong to Bring Revenue AI to Boomi Agentstudio Gong goes beyond capturing deal activity to surface real-time insights into risk, buyer intent, competitive dynamics, and key engagement signals. That intelligence moves from conversation to coordinated action, flowing across CRM, ERP, product, and operational systems with the governance and security tha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom